Primary source: Inspections and Compliance
Sevabertinib received accelerated approval for a broader indication including patients who have not received prior systemic therapy.
This regulatory change allows more patients with specific HER2 mutations to access sevabertinib, potentially improving outcomes for those with aggressive lung cancer.
Update labeling and handle regulatory documentation to reflect the new approved indication for sevabertinib, including dosage guidance of 20 mg orally twice daily.
Regulatory Intelligence Lead
Review in the next regulatory intelligence cycle.
Update labeling and handle regulatory documentation to reflect the new approved indication for sevabertinib, including dosage guidance of 20 mg orally twice daily.
On September 9, 2026, the FDA granted accelerated approval to sevabertinib (Hyrnuo) for adults with locally advanced or metastatic non-squamous NSCLC whose tumors have HER2 TKD activating mutations, expanding its use for this treatment population.
What changed: Sevabertinib received accelerated approval for a broader indication including patients who have not received prior systemic therapy.
Why it matters: This regulatory change allows more patients with specific HER2 mutations to access sevabertinib, potentially improving outcomes for those with aggressive lung cancer.
Practical implication: Update labeling and handle regulatory documentation to reflect the new approved indication for sevabertinib, including dosage guidance of 20 mg orally twice daily.
Published from the regulator source ingestion pipeline after PV impact triage.
Manufacturers must act on and respond to FSNs promptly, ensuring timely notifications are sent out as dictated by the FSNs issued.
Integrate new protocols for screening and dosage adjustments for fluoropyrimidines in all healthcare establishments, alongside increased monitoring of DPD screening outcomes within pharmacovigilance processes.
Healthcare providers must implement mandatory DPD screening for all patients before starting fluoropyrimidine treatment and enhance monitoring for adverse effects.
Importers of the affected glass containers must guarantee the payment of the anti-dumping duty for a period of six months from the effective date.
